ReviewFrontiers in oncology2026
Mushroom-derived polysaccharides in cancer immunotherapy: mechanisms, human evidence, and translational priorities.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mushroom-derived polysaccharides are widely promoted as anticancer immune modulators, but interpretation is weakened by imprecise product identity, chemically non-equivalent preparations, and extrapolation across evidence levels. This critical narrative review evaluates beta-glucans, heteropolysaccharides, polysaccharide-protein complexes, crude fractions, modified derivatives, and multicomponent extracts as preparation-specific adjunct candidates. Receptor-level evidence is strongest for general fungal beta-glucan systems, particularly Dectin-1/Syk/CARD9 signaling and conditional complement receptor 3 cooperation; direct transfer of those mechanisms to individual mushroom preparations requires product-specific causal testing. Selected animal studies support myeloid remodeling, dendritic-cell and natural-killer-cell effects, and T-cell activation, but route, exposure, product characterization, and model limitations constrain translation. Human evidence remains heterogeneous: historical randomized PSK studies reported benefit in specific adjuvant chemotherapy settings, a later phase III lentinan trial was negative for overall survival, and small maitake,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.